Anti-PD-L1 (Avelumab), Human IgG1 Antibody

• Data sheet: View or download

The research-grade biosimilar is a human IgG1 lambda monoclonal antibody that specifically targets programmed death-ligand 1 (PD-L1). Binding of PD-L1 to the PD-1 and B7.1 receptors occurs on T cells and antigen-presenting cells that results in suppression of cytotoxic T-cell activity, T-cell proliferation, and cytokine production. The antibody binds PD-L1 through the FG loops and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1. This releases the suppression of immune responses and promotes the inhibition of tumor growth. Studies show that the drug is capable of inducing antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. The original drug received FDA approval to treat Merkel cell cancer. It is currently been used in immunotherapy for several cancers